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ABSTRACT
Mucoepidermoid carcinoma (MEC) is the most common malignancy of salivary 
glands. The response of MEC to chemotherapy is unpredictable, and recent advances 
in cancer biology suggest the involvement of cancer stem cells (CSCs) in tumor 
progression and chemoresistance and radioresistance phenotype. We found that 
histone acetyltransferase inhibitors (HDACi) were capable of disrupting CSCs in 
MEC. Furthermore, administration of HDACi prior to Cisplatin (two-hit approach) 
disrupts CSCs and sensitizes tumor cells to Cisplatin. Our findings corroborate to 
emerging evidence that CSCs play a key role in tumor resistance to chemotherapy, 
and highlights a pharmacological two-hit approach that disrupts tumor resistance to 
conventional therapy.
INTRODUCTION
Malignant salivary gland tumors are uncommon 
lesions, representing around 3-5% of all head and neck 
neoplasms [1, 2]. Mucoepidermoid carcinoma (MEC) 
is the most common malignant salivary tumor, which 
comprises approximately 30% of all salivary malignances 
[2, 3].
Current treatment of MEC encompasses surgical 
resection with eventual adjuvant radiotherapy, which 
frequently leads to functional and aesthetic complications 
[3-6]. Chemotherapy is often reserved for recurrent 
and metastatic tumors. Administration of single-agent 
or combination therapy shows activity, but the overall 
response rates are unsatisfactory and short-lived [4, 6]. 
Emerging evidence suggests that the modest response of 
tumor cells to therapy, which results in high recurrence 
rates and poor survival, are associated with the presence 
of cancer stem cells (CSCs) [7, 8]. Indeed, the presence 
of CSCs is considered as a prognosis determinant in 
several cancers, including those of the ovary, lung, 
breast and head and neck [9-12]. Resistance of tumors 
to chemotherapy is associated with the gain of new 
mutations, activation of specific signaling pathways, the 
presence of CSCs, and histone modifications as epigenetic 
modulators of cancer behavior [12-16]. Interestingly, 
histone modifications may play a major role in the 
establishment of CSCs and tumor cells that are resistant 
to chemotherapy [17]. By dynamically modulating tumor 
chromatin folding, histone deacetylation leads to reduced 
transcription of differentiation genes and activation 
of stem cell genes. These results in the maintenance of 
tumor cells in a quiescent stage, making them more 
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resistant to conventional intercalating agents compared 
to non-quiescent tumor cells [18, 19]. In fact, changes 
in DNA folding induce various cellular phenotypes 
mediated by cell type-specific chromatin organization 
[20]. We have recently shown that pharmacological 
acetylation of chromatin in head and neck squamous 
cell carcinoma (HNSCC) results in dramatic changes on 
cellular phenotype [21]. We also found that acetylation of 
tumor histones by histone deacetylase inhibitors (HDACi) 
abrogates tumor resistance of HNSCC to chemotherapy 
[12]. Indeed, similar findings have been reported in 
other tumors including non-small cell lung cancers, 
osteosarcomas, mesotheliomas, and cervical cancer [22-
25]. Further, HDACi disrupts tumorspheres, suggesting a 
direct role of chromatin organization in the maintenance 
of CSCs [12].
Recent advances in MEC biology have occurred 
through the identification of a subpopulation of CSCs 
with high tumorigenic properties [26]. However, the role 
of CSCs in chemoresistance in MEC is poorly understood. 
We investigated the effects of HDACi and Cisplatin in 
CSCs derived from two MEC cell lines and found that 
CSCs did not respond to Cisplatin. In fact, Cisplatin 
triggered the accumulation of CSCs in one of the MEC 
tumor cell lines. We next examined whether HDACi had 
any effects over the population of CSCs and found that 
an extremely low concentration of HDACi is sufficient to 
deplete MEC CSCs. Further, sensitization of tumor cells 
with HDACi prior to treatment with Cisplatin depleted 
MEC CSCs, surpassing the inhibitory effects of HDACi 
alone. In addition to improving the therapeutic effects of 
Cisplatin, HDACi also reduces the half dose inhibitory 
concentration (IC50) of Cisplatin in MEC tumor cells.
Our findings suggest that treating MEC with drugs 
that induces chromatin acetylation result in the destruction 
of CSCs and reduces chemoresistance of MEC cells.
RESULTS
MEC have mixed levels of histone H3 acetylation
The acetylation status of histones is controlled by 
the balance between histone deacetylase (HDAC) and 
histone acetyltransferase (HAT) activity. Changes in 
histone acetylation have a direct effect on many cellular 
functions, including cellular morphology and response 
to environmental cues [21, 27-29]. Interestingly, we 
found that normal human salivary glands have different 
expression patterns of histone H3 (Lys9) within different 
cell populations. We found that acinar cells (Figure 
1A_#1) were hypoacetylated compared to epithelial 
cells from the intercalated (Figure 1A_#2) and secretory 
(Figure 1A_#3) ducts. Similar to normal salivary glands, 
MEC were comprised of a heterogeneous population of 
epithelial cells in distinct stages of cellular differentiation 
and histone H3 (Lys9) acetylation (Figure 1B_#1). Tumor 
cells showing squamous and intermediate differentiation 
had high levels of histone H3 acetylation (mean: 
66.92±4.441) (Figure 1B_#2 arrowhead), but a smaller 
number of tumors cells were negative for histone H3 
(Figure 1B_#2 arrow). Mucous-like tumor cells were 
primarily negative for histone H3 (Mean: 5±1.132) (Figure 
1B_#3 arrow) compared to differentiated squamous cells 
(Figure 1B_#3 arrowhead). Quantification revealed that 
histone H3 was significantly acetylated in squamous and 
intermediate differentiated cells compared to mucous-like 
tumor cells from thirteen cases of MEC (*** p<0.001) 
(Figure 1C).
Tumor cell lines derived from primary and 
metastatic MEC were established in the Nör laboratory 
at the University of Michigan [26, 30]. We examined 
histone H3 acetylation in 5 MEC cell lines, including 
UM-HMC1, UM-HMC2, UM-HMC3A, UM-HMC3B, 
and UM-HMC5. With the exception of UM-HMC2, 
the other 4 MEC cell lines had detectable histone H3 
acetylation (Figure 1D). As previously reported, MEC 
cell lines generate tumors following engraftment onto 
SCID mice [30]. Interestingly, in addition to generating 
viable xenografts, MEC cell lines recapitulate many of the 
features of the primary tumors. In general, solid tumors 
generated from engrafted MEC cell lines were primarily 
comprised of squamous-like tumor cells and patches of 
mucous-like tumor cells (Supplementary Figure 1A). 
Tumor cell lines derived from xenografts also retained 
cytokeratin 5 expression suggesting the presence of tumor 
cells with epidermoid differentiation, along Vimentin 
expression, which are commonly observed in MEC 
(Supplementary Figure 1B) [31, 32].
Collectively, these findings strongly suggest that 
MEC cell lines retain multipotent ability to differentiate 
into squamous and mucous-like cellular components. 
Nonetheless, these cell lines differ in chromatin acetylation 
(histone H3 lys9 acetylation), suggesting they will display 
differential gene transcription patterns and distinct cellular 
behavior.
MEC cell lines generate tumorspheres
Solid tumors are often refractory to current 
therapies, and this is the case with MEC [4-6]. 
New findings suggest that CSCs are involved in the 
development of chemoresistance and radioresistance 
[7, 8, 33]. These observations have sparked interest in 
developing therapeutic strategies targeting CSC function 
and fate. Growing tumor cells in ultra-low adhesion 
conditions generates tumor spheres of different sizes 
and shapes [34]. We have recently demonstrated that 
the generation of tumor spheres is a useful technique 
for enriching CSCs in vitro and is of interest for 
developing new therapies targeting CSCs [35]. Epithelial 
spheres advent from normal epithelial cells and tumor 
spheres are classified into three groups, including 1) 
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holospheres, which are characterized by the formation 
of a large circular sphere with regular borderlines; 2) 
paraspheres, which are small sphere-like structures with 
fragmented borderlines; and 3) merospheres, which form 
sphere-like structures with intermediated morphology 
between holospheres and paraspheres [34, 35]. Different 
populations of head and neck CSCs grown under ultra-
low adhesion are characterized by distinct biological 
behavior and CSC content. While holospheres present 
low proliferation index, it can accumulate more ALDH 
positive cells compared to mero and paraspheres and 
efficiently invade a reconstituted basal membrane layer. 
Holospheres is also characterized by an improved ability 
to adhere to substrates and to retain the ability to form 
holo, mero, and paraspheres upon serial passages [35]. 
Most interesting, tumor cells have also shown to retain 
its stem cell hierarchies upon serial cellular passages 
that suggest the maintenance of an asymmetrical cellular 
division. Of interest, serial passages also enhanced stem 
cell self-renewal [36].
We found that all MEC cell lines generated tumor 
spheres when grown under ultra-low adhesion conditions 
(Figure 2A). Interestingly, the MEC cell lines showed 
differential efficiency in forming tumor spheres. UM-
HMC2 cells had low efficiency in generating tumor 
spheres, with a mean of 3 spheres per 2,500 MEC cells 
compared to metastatic UM-HMC3B cells, which 
produced a mean of 47.33 tumor spheres per 2,500 
MEC cells. UM-HMC1, UM-HMC3A, and UM-HMC5 
generated an intermediate number of tumor spheres 
(means of 10.33, 24, and 16.33, respectively). Tumor 
colonies and spheres are also generated by other malignant 
tumor cell lines, including those of the pancreas [37], 
breast [9], prostate [38], colon [39], head and neck [36], 
and, most recently, MEC [40, 41].
Interestingly, with the exception of UM-HMC2 
cells, all other MEC cells generated all three subtypes of 
tumor spheres (Figure 2B). However, each cell line was 
unique in the number and type of spheres that were formed 
(Figure 2C). While UM-HMC1 and UM-HMC2 cells 
had a limited potential to generate viable spheres, UM-
Figure 1: Levels of ac. Histone H3 in salivary glands and MEC. A. Representative expression of ac. histone H3 in acinar 
cells (A_#1), intercalated duct (A_#2) and secretory ducts (A_#3) of salivary glands. B. MEC has mixed levels of ac. histone H3, with 
epidermoid and intermediate cells showing both positive and negative staining; in addition, mucous-like tumor cells negative for ac. histone 
H3 are found next to positive epidermoid tumor cells. C. Quantification of ac. histone H3 using tumor tissue reveals increased acetylation in 
squamous and intermediate tumor cells (red) compared to mucous-like tumor cells (green). D. Western blot analysis of baseline expression 
of ac. histone H3 in UM-HMC1, UM-HMC2, UM-HMC3A, UM-HMC3B, and UM-HMC5 tumor cells. GAPDH served as a loading 
control.
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HMC3A, UM-HMC3B, and UM-HMC5 cells generated 
a larger number of tumor spheres (Figure 2C). In 
addition, the proportion of holospheres, merospheres, and 
paraspheres produced by UM-HMC3A, UM-HMC3B, and 
UM-HMC5 cells were similar, but meroclones accounted 
for the majority of tumor spheres followed by holospheres 
and then paraclones (Figure 2C).
Because UM-HMC3A, UM-HMC3B, and UM-
HMC5 cells yielded the highest number of tumor spheres, 
we used these cells for our remaining experiments. The 
presence of CSCs in UM-HMC3A, UM-HMC3B, and 
UM-HMC5 cells was further confirmed by detection 
of aldehyde dehydrogenase (ALDH), a well-known 
biomarker for various normal and cancer stem cells 
(Supplementary Figure 2) [42-46].
Figure 2: MEC cell lines generate tumor spheres. A. All MEC cell lines generate tumor spheres when grown in ultra-low 
adhesion conditions. B. Representative tumor spheres from MEC cells showing holosphere-, merosphere-, and parasphere-like shapes. C. 
Quantification of the total number of holospheres, merospheres, and paraspheres individually produced by UM-HMC1, UM-HMC2, UM-
HMC3A, UM-HMC3B, and UM-HMC5 cell lines.
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Cisplatin differentially affects the population of 
CSCs in MEC cell lines
We next examined the effects of Cisplatin on 
CSCs. We first determined the IC50 of Cisplatin in each 
MEC cell line. UM-HMC3A had an IC50 of 8.47 μg/
ml, which was lower than UM-HMC3B with an IC50 of 
9.17 μg/ml and UM-HMC5 with an IC50 of 10.7 μg/ml 
(Figure 3A). We then treated MEC cells with Cisplatin 
at the appropriate IC50 concentrations and performed 
a sphere forming assay to determine the effects of 
Cisplatin on tumor cells enriched for CSC (Figure 
3B). Cisplatin alone sufficiently reduced the number of 
viable tumor spheres in all three MEC cell lines (UM-
Figure 3: MEC tumor cell lines respond differentially to Cisplatin. A. Determination of the IC50 of Cisplatin in MEC cells. 
B. Cisplatin reduces the number of tumor spheres in UM-HMC3A, UM-HMC3B, and UM-HMC5 (**p<0.005; ***p<0.001). C. ALDH 
activity following administration of Cisplatin. ALDH-positive UM-HMC3A cells do not respond to Cisplatin, while UM-HMC3B are 
highly sensitive to Cisplatin. Cisplatin increases the number of ALDH-positive tumor cells in UM-HMC5.
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HMC3A **p<0.005; ***p<0.001 for UM-HMC3B 
and 5). Interestingly, when using ALDH+ tumor cells 
to assess the effect of Cisplatin on CSCs, we observed 
that each MEC cell line reacted differently (Figure 3C). 
Although CSCs derived from UM-HMC3A did not 
respond to Cisplatin (ns p>0.05), UM-HMC3B CSCs 
showed high sensitivity to Cisplatin (*** p<0.001). The 
number of ALDH+ cells in UM-HMC5 CSCs increased 
from 4.1% in response to vehicle to 6.8% in response 
to Cisplatin (*** p<0.001). The discrepancy between 
the tumorsphere forming assay and the total number 
of ALDH+ cells prompted us to determine whether the 
subtypes of tumorspheres would respond differently 
to chemotherapy, as we have previously observed in 
HNSCC, and if differential responses would be due to 
CSCs with distinct behavior and ability to respond to 
chemotherapy. Indeed, we found that holospheres were 
more sensitive to Cisplatin compared to merospheres 
and paraspheres (Supplementary Figure 3A, 3B, 3C). 
Remarkably, paraspheres were completely refractory 
to therapy in two MEC cell lines (UM-HMC3A and 
3B) (Supplementary Figure 3A and 3B). Similarly, 
paraspheres derived from UM-HMC5 showed less 
response to Cisplatin compared to holospheres and 
merospheres (Supplementary Figure 3C).
These unexpected results suggest that we can 
better understand the biology of tumor cells during 
chemotherapy through the combination of ALDH 
enzymatic detection and the enrichment of CSCs using 
an ultra-low adhesion culture technique. While the 
total number of tumorspheres suggests that MEC CSCs 
are sensitive to cisplatin, ALDH expression suggests 
that they are either non-responsive or proliferate in 
the response to cisplatin. Moreover, classification 
of tumorspheres into holospheres, merospheres, and 
paraspheres helps to identify which MEC tumors cells 
will be resistance to cisplatin (paraspheres). Indeed, 
our findings corroborate with the observations in MEC 
patients in which single-agent or combination therapy is 
effective for short periods of time, suggesting that tumor 
rebound may be associated with the accumulation of 
CSC [4, 6].
SAHA efficiently reduces CSCs in MEC cell lines
The HDACi SAHA (Vorinostat) has been used in 
several types of tumors [47, 48]. SAHA targets histone 
and nonhistones substrates by removing the acetyl moiety 
from the lysine residues of proteins that include core 
histones. SAHA act as an inhibitor of classes I, and II of 
histone deacetylases inhibiting the proliferation of tumor 
cells [49, 50], inhibition of mitosis [51, 52], cell cycle arrest 
[53] differentiation or apoptosis [54] with little toxicity 
to normal cells. Administration of SAHA induces the 
acetylation of tumor chromatin as detected by ac.H3 (Lys9) 
(Supplementary Figure 4A). Acetylation of core histone 
proteins also drives cellular differentiation while restricting 
transformation [55, 56]. We assessed the IC50 of SAHA in 
adherent MEC cell lines. UM-HMC3A were very resistant 
to SAHA (1.15 μM) compared to UM-HMC5 (0.4 μM) 
and UM-HMC3B (0.3 μM) (Supplementary Figure 4B). 
Additionally, we examined the inhibitory effects of SAHA in 
CSCs. To accomplish this, we enriched for CSCs by seeding 
MEC cells in ultra-low adhesion conditions to generate 
tumor spheres and determined the IC50 for the tumor spheres 
produced by each cell line (Figure 4A). Administration of 
SAHA alone was able to efficiently disrupted the ability of 
MEC cells to generate tumor spheres in a dose-dependent 
manner (Figure 4A). Upon analysis of all subpopulation 
of spheres composed by holo, mero and paraspheres we 
observed that the effect of SAHA was homogeneous 
throughout all tumor spheres in a dose-dependent way 
(Supplementary Figure 4C).
Tumor spheres grown in ultra-low attachment 
conditions were more sensitive to SAHA than tumor cells 
grown in monolayers (UM-HMC3A_6.4 folds reduction, 
UM-HMC3B_3.3 folds reduction, and UM-HMC5_3.6 
folds reduction (Figure 4B).
We next examined the effects of SAHA on ALDH+ 
CSCs. The number of ALDH+ cells was reduced following 
treatment with SAHA at the concentrations used in tumor 
spheres (Figure 4C). Unlike CSCs from UM-HMC3A (ns 
p>0.05), the reduction in CSCs from UM-HMC3B and 
UM-HMC5 was significant (*** p<0.001). The resistance 
of UM-HMC3A to SAHA (Supplementary Figure 4B) 
may explain why we did not see statistically significant 
reductions in CSCs from this cell line.
Unlike Cisplatin, SAHA did not increase the number 
of ALDH+ cells or the accumulation of paraspheres.
Sequential administration of SAHA and 
Cisplatin (two-hit approach) reduces the number 
of CSCs, prevents resistance in MEC, and 
reduces the amount of Cisplatin required to 
achieve IC50 levels
Previous studies, including from our group, have 
shown that SAHA increases the sensitivity of solid tumors 
to Cisplatin [12, 57-60]. Resistance to chemotherapy is 
a complex and poorly understood process that results 
from many factors, including activation of resistance 
pathways, such as NFκB signaling, and the presence of 
CSCs [12, 21]. Because different mechanisms underlie 
resistance, solid tumors often show a mixed response 
to therapy. We showed that CSCs from MEC cell lines 
respond differently to Cisplatin. We have previously 
found that histone deacetylation disrupts HNSCC tumor 
spheres [12, 21]. Our goal was to deliver a two-hit therapy 
that would sensitize CSCs to Cisplatin by first inducing 
histone deacetylation (SAHA) (Figure 5A). This approach 
resulted in a homogeneous response of all MEC tumor cell 
lines to Cisplatin, with significant reductions in CSCs, as 
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determined by ALDH levels (Figure 5B) and a reduction 
in tumorspheres (Supplementary Figure 5); these effects 
were not observed following treatment with Cisplatin or 
SAHA alone (Figure 5C).
We next examined whether the reduction in CSCs 
translated into the sensitization of MEC tumor cells to 
Cisplatin. MEC cells were sensitized with SAHA for 24 
hours followed by administration of Cisplatin (Figure 5D). 
SAHA sensitized MEC cells to Cisplatin, resulting in a 
reduction of the IC50 from 8.4 μg/ml to 5.5 μg/ml for UM-
HMC3A, from 9.1 μg/ml to 4.4 μg/ml for UM-HMC3B, 
and from 10.7 μg/ml to 4.2 μg/ml for UM-HMC5 (Figure 
5E). In addition to suggesting that the two-hit therapy is 
more efficient in ablating CSCs, our data also shows that 
this strategy reduces the amount of Cisplatin required to 
achieve IC50 levels.
Figure 4: SAHA reduces CSCs in MEC cell lines. A. Determination of IC50 of SAHA in tumor spheres derived from UM-HMC3A, 
UM-HMC3B, and UM-HMC5 cell lines. B. Tumor cells derived from tumor spheres show increased sensitivity to SAHA compared to 
tumor cells growing in a monolayer. C. Low levels of SAHA (IC50 for tumor spheres) reduce the number of ALDH-positive tumor cells. 
Notably, UM-HMC3A did not respond to SAHA, while CSCs were significantly reduced in UM-HMC3B and UM-HMC5 (*** p<0.001).
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DISCUSSION
The treatment for salivary MEC includes surgical 
resection and eventual adjuvant radiotherapy because 
this disease is resistant to conventional chemotherapy 
[3-6]. Recent studies suggest that CSCs play a major 
role in tumor relapse and treatment failure [7, 33, 47]. 
We found that all MEC cells lines contain CSCs that 
form spheres when cultured in ultra-low adhesion 
conditions. In addition, MEC cell lines contain different 
numbers of CSCs, distinct abilities to generate tumor 
spheres, and differential capacities to form the various 
subtypes of tumor spheres. We further observed that 
MEC have heterogeneous H3 acetylation patterns. For 
Figure 5: SAHA sensitizes tumor cells to Cisplatin. A. Representation of the “two hit approach” using SAHA 24hrs prior to Cisplatin 
to sensitize tumor cells. B. The two-hit approach significantly reduces ALDH-positive cells (*p<0.05; ***p<0.001). C. The table depicts 
the efficiency of SAHA in sensitizing all MEC tumor stem cells to Cisplatin compared to the administration of Cisplatin or SAHA alone. D. 
Graphic determination of the new IC50 of Cisplatin after sensitization with SAHA. E. Note the reduction in the IC50 of Cisplatin is 1.52 fold in 
UM-HMC3A, 2.06 fold in UM-HMC3B, and 2.54 fold in UM-HMC5 upon sensitization with SAHA compared to Cisplatin alone.
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example, tumors cells with squamous and intermediate 
differentiation are commonly acetylated, but 
hypoacetylated tumor cells are also present within the 
tumor mass. Interestingly, mucous-like tumor cells are also 
hypoacetylated. Indeed, the level of histone acetylation 
correlates with the transcriptional activity of the cell 
[61, 62]. Histone acetylation is associated with increased 
transcription of genes involved in differentiation, and 
histone deacetylation is associated with reduced gene 
transcription and/or activation of stem cell-associated 
genes. Changes in the levels of histone acetylation has 
been observed in various processes, including the initiation 
and progression of cancer, cellular plasticity, inflammation, 
maintenance of CSCs, and activation of tumor resistance 
pathways [12, 21, 56]. We have observed that certain head 
and neck tumor cell lines are prone to histone deacetylation 
upon administration of chemotherapy [12]. Moreover, 
these cells are characterized by increased resistance 
to chemotherapy. Given that histone deacetylases are 
involved in transcriptional repression, we hypothesize that 
histone deacetylation in tumor cells selectively activates 
stem cell-associated genes, resulting in chemoresistance. 
If true, pharmacological inhibition of histone deacetylases 
in all tumors cells would disrupt signaling programs 
associated with maintenance of CSCs, thereby reducing 
the resistance of MEC to Cisplatin. Evidence of the 
efficacy of such combined therapy has been demonstrated 
in Hodgkin’s Lymphoma, cervical cancer, ovarian cancer, 
head and neck squamous cell carcinoma, and pancreatic 
cancer [12, 57-60, 63]; however, the mechanism of action 
remain elusive. Our work focuses on the response of 
CSCs to chemotherapy. Interestingly, we found that CSCs 
derived from MEC cell lines show variable responses to 
Cisplatin. While CSCs derived from UM-HMC3A did 
not respond to Cisplatin, CSCs derived from a metastatic 
MEC (UM-HMC3B) were sensitive to this drug. Perhaps 
the most interesting result came from UM-HNC5 cells, in 
which Cisplatin induced an abrupt accumulation of CSCs. 
Although unexpected, CSCs in other tumors accumulate 
in response to chemotherapy [64-66]. Unlike Cisplatin, 
SAHA reduced the number of tumor spheres and ALDH+ 
cells in all tumor cell lines. These results suggest 
that pharmacological acetylation of tumor cells has a 
direct impact on the viability of CSCs. Indeed, HDACi 
sensitizes tumor cells to chemotherapy and radiotherapy 
[22-25]. Although poorly understood, HDACi-induced 
decondensation of chromatin makes DNA more permeable 
to chemotherapeutic agents [12, 58]. In lung cancer, 
HDACi increases apoptosis of tumor cells through a 
Bax-dependent mechanism [67]. As a molecular target of 
HDACi, increased acetylation of Ku-70 and a reduction 
in its DNA-binding affinity occur in prostate cancer [68].
Several other mechanisms have been associated 
with chemotherapy resistance of CSCs. Among them, drug 
efflux play a role in tumor resistance to chemotherapy by 
pumping out anticancer drugs from cancer cells. Recent 
findings have shown that glioma CSCs present high 
drug efflux capability in a mechanism that involves the 
activation of ABC transporters [69]. Such enhanced drug 
efflux was also observed in hepatocellular carcinomas 
(HCC) CSCs in a mechanism dependent on the activation 
of Akt [70]. Remarkably, a key component of anticancer 
drug resistance observed on CSCs is the expression of high 
levels of ALDH [71-74]. Targeted inhibition of ALDH 
activity results in reduced chemoresistance of gastric, 
lung cancer and leukemic cells [71, 75]. Altogether, high 
levels of ALDH seems to be required to maintain the 
population of CSCs and to confer resistance of CSCs to 
cancer therapy. Interestingly, the expression of Notch 
gene, previously associated with the maintenance of stem 
cells [76], acts as an upstream regulator of ALDH activity 
[77]. Notch itself is negatively regulated by histone 
acetyltransferases like Tip60 through acetylation [78]. 
These evidences align with our findings in which histone 
acetylation (mediated by the histone deacetylase inhibitor 
SAHA) result in a reduction of ALDH + cells leading to an 
enhanced sensitivity of MEC cells to Cisplatin.
The efficiency in reducing the number of CSCs 
through administration of SAHA suggests that our two-hit 
therapeutic strategy is effective, as evidenced by a 27-fold 
reduction in ALDH+ cells. In contrast to their combination, 
SAHA or Cisplatin alone did not efficiently reduce CSCs.
SAHA was also effective in reducing the 
concentration of Cisplatin needed to achieve IC50. This 
result is of particular interest for patients that fail their 
initial chemotherapy cycles due to high toxicity [79].
In summary, we presented evidence that 
administration of HDACi efficiently disrupts MEC-
containing CSCs and reduces the concentration of 
Cisplatin required to achieve IC50. Our research helps 
to clarify the mechanism of action of HDACi and 
highlights an efficient therapeutic strategy for managing 
MEC. Future in vivo studies are required to confirm the 
feasibility of this strategy.
MATERIALS AND METHODS
Tissue microarray (TMA)
TMAs were constructed using tissue samples 
from thirteen mucoepidermoid carcinomas, salivary 
gland tumors and control normal salivary gland tissues 
using a manual tissue arrayer (Sakura Co, Japan). Three 
representative cylindrical cores of 2.0 mm diameter were 
removed from each tissue block and arranged sequentially 
in a ready-to-use paraffin block (Sakura Co, Japan), 
according to Fonseca et al [80].
Immunohistochemistry and immunofluorescence
For immunohistochemical staining, the slides 
were incubated overnight with anti-acetyl histone H3 
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(Cell Signaling, Danvers, MA, USA) and then anti-
rabbit secondary antibody for 60 minutes at RT (Vector 
laboratories, Burlingame, CA, USA). HRP was detected 
using the Vector DAB detection system, and the slides 
were counterstained with Mayer’s hematoxylin. For 
immunofluorescence assays, the samples were fixed with 
methanol at −20°C for 6 minutes, blocked with 0.5% 
(v/v) Triton X-100 in PBS and 3% (w/v) bovine serum 
albumin (BSA) and incubated with anti-Vimentin (Thermo 
Scientific, Waltham, MA, USA), anti-BMI-1 (Millipore, 
Billerica, MA, USA), anti-Pan-cytokeratin (Cell 
Signaling, Danvers, MA, USA), anti-phospho S6 (Cell 
Signaling, Danvers, MA, USA) and ac.H3 (Lys9) (Cell 
Signaling, Danvers, MA, USA). Cells were then incubated 
with FITC- or TRITC-conjugated secondary antibody 
and stained with Hoechst 33342 (Sigma-Aldrich Corp., 
St. Louis, MO, USA) to visualize DNA content. Images 
were taken using a QImaging ExiAcqua monochrome 
digital camera attached to a Nikon Eclipse 80i Microscope 
(Nikon, Melville, NY) and visualized with QCapturePro 
software.
Cell lines
Mucoepidermoid carcinoma cells lines UM-HMC1, 
UM-HMC-2, UM-HMC-3A, UM-HMC-3B and UM-
HMC5 were originally established at the University of 
Michigan School of Dentistry and described by Warner 
et al (2013). Cells lines were maintained in a 5% CO2 
humidified incubator at 37ºC and cultured in RPMI 1640 
(Thermo Scientifics, Waltham, MA, USA) supplemented 
with 10% fetal bovine serum (Thermo Scientifics), 
1% antibiotic (Invitrogen, Carlsbad, CA, USA), 1% 
L-glutamine (Invitrogen), 20 ng/ml epidermal growth 
factor (Sigma–Aldrich, St. Louis, MO, USA), 400 ng/
ml hydrocortisone (Sigma–Aldrich), and 5 μg/ml insulin 
(Sigma–Aldrich). Cells were treated with SAHA (Cayman 
Chemical Company Ann Arbor, MI, USA) and Cisplatin 
(Sigma-Aldrich, St. Louis, MO, USA).
MEC xenograft-derived tumor tissue samples
UM-HMC-derived xenograft tumors were 
established in the Nör laboratory at the University of 
Michigan. Briefly, tumors were surgically retrieved when 
they reached 800–1000 mm3, fixed overnight in 10% 
buffered formalin (Fisher) at 4°C, and paraffin embedded 
[30]. Unstained slides were sectioned at 3 μm thickness 
and processed for hematoxylin and eosin (H&E) staining.
IC50 determination
We used the CellTiter 96TM AQueous non-
radioactive cell proliferation kit (Promega) to determine 
concentrations of Cisplatin and SAHA that inhibited 
cell proliferation by 50% (IC50). Cell proliferation was 
determined by reduction of MTS (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxy phenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt) following the manufacturer’s 
protocol. In brief, 2500 cells were plated into 96-well 
plates and treated in triplicate with control (vehicle), 
SAHA (0.1, 0.25, 0.5, 1.0, 2.5, 5.0 and 10.0 μM), or 
Cisplatin (2.5, 5.0, 7.5, 10.0, 12.5, 15.0, 17.5 and 20.0 μg/
ml) for 24 h. Cells were incubated with MTS at 37°C for 
4h, and the results were assessed by absorbance (Bio-Tek 
EL-311, Bio-Tek Instruments) at 490 nm.
Tumor sphere formation assay
MEC cells were plated on ultra-low attachment 
plates and grown for 5 days. Sphere formation was 
observed daily. SAHA was administered on the first day 
of culture to evaluate sphere formation in the presence 
of histone H3 acetylation. Cisplatin was added on day 5 
of culture for 24 hours. Spheres growing in suspension 
were collected at day 6, transferred to a glass slide by 
centrifugation (1500 rpm, 4ºC, 10 minutes) using a 
cytospin system, and fixed with PFA for 15 minutes at RT.
Flow cytometry
CSCs derived from MEC tumors were identified 
by flow cytometry for ALDH (aldehyde dehydrogenase) 
activity using the Aldefluor kit (StemCell Technologies, 
Durham, NC, USA) according to the manufacturer’s 
instructions. Briefly, UM-HMC3, UM-HMC3B, and 
UM-HMC5 cells were treated with SAHA and/or 
Cisplatin at concentrations determined by the IC50 studies. 
Cells were then suspended with uncharged Aldefluor 
substrate BAAA (BODIPY-aminoacetaldehyde) that is 
converted intracellularly into negative charged BAA- 
by endogenous ALDH resulting in the production of 
bright fluorescence. The Aldefluor substrate BAAA 
(BODIPY-aminoacetaldehyde), and negative control 
(diethylaminobenzaldehyde, a specific ALDH inhibitor) 
was incubated for 45 minutes (optimized for MEC cells) at 
37°C. All samples were analyzed in a FACS Canto IV (BD 
Biosciences, Mountain View, CA, USA, 520-540nm) at 
the University of Michigan Flow Cytometry Core. Gates 
were determined using DEAB control. ALDH profile was 
determined in MEC cells upon incubation of Aldefluor for 
45 minutes. ALDH bright tumor cells were determine by 
an overlay of DEAB treated cells and ALDH bright cells. 
Briefly, tumor cells were initially gated using a forward 
scatter (FSC) and side scatter (SSC) dot plot to eliminate 
debris. The fluorescence channel is initially setup using 
DEAB treated cells area (low bright or negative cells). 
The percentage of ALDH bright cells was gated outside of 
DEAB treated cells area (R2 or ALDH). Each tumor cell 
line was analyzed using its own DEAB x SCC settings to 
account for differences in the cell surface and complexity.
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Immunoblotting
Cells were harvested in RIPA buffer and briefly 
sonicated. Protein lysates (30 μg) were separated by 
10% to 15% SDS–PAGE and transferred to a polyvinyl 
difluoride membrane (Immobilon) (Millipore). Membranes 
were blocked in 0.1 M Tris (pH 7.5), 0.9% NaCl and 
0.05% Tween-20 (TBS-T) with 5% nonfat dry milk. 
Membranes were incubated with anti-acethyl-Histone H3 
(Lys9) (Cell Signaling). GAPDH (Calbiochem) served as 
a loading control. The reaction was visualized using ECL 
SuperSignal West Pico Substrate (Pierce Biotechnology).
Statistical analysis
All statistical analysis was performed using 
GraphPad Prism (GraphPad Software, San Diego, CA). 
Statistical analysis of total number of squamous and 
mucous-like tumor cells positive to ac.H3 was performed 
using t-test. Statistical analysis of total number of tumor 
spheres, and the % of tumor cells positive for ALDH 
receiving CDDP alone, SAHA alone, and the combination 
of SAHA and CDDP was performed using two-way 
analysis of variance (ANOVA) followed by Bonferroni 
posttest. Percentage of UM-HMC cells presenting 
acetylated upon SAHA treatment was analyzed using one-
way ANOVA followed by Tukey’s Multiple Comparison 
Test. Asterisks denote statistical significance (* p < 0.05; 
** p < 0.01; *** p < 0.001; and NS p > 0.05). All samples 
were normalized to 100% following nonlinear regression 
to fit the data to the log(inhibitor) vs. response (variable 
slope) curve.
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